Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 20/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.78 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.63 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5010624 | 0.96 | ADORA1 (1.00) | ADORA1ADORA3ADORA2BADORA2A | |
| SCHEMBL5005323 | 0.95 | ADORA1 (0.91) | ADORA1ADORA3ADORA2BADORA2A | |
| SCHEMBL5010548 | 0.95 | ADORA1 (0.94) | ADORA1ADORA3ADORA2BADORA2A | |
| SCHEMBL5012028 | 0.92 | ADORA1 (0.88) | ADORA1ADORA3ADORA2BADORA2A | |
| SCHEMBL5008325 | 0.91 | ADORA1 (0.84) | ADORA1ADORA3ADORA2BADORA2A | |
| SCHEMBL3306762 | 0.91 | ADORA1 (0.86) | ADORA1ADORA3ADORA2BADORA2A | |
| SCHEMBL5008398 | 0.91 | ADORA1 (0.83) | ADORA1ADORA3ADORA2BADORA2A | |
| SCHEMBL5008337 | 0.91 | ADORA1 (0.86) | ADORA1ADORA3ADORA2BADORA2A | |
| SCHEMBL5008527 | 0.90 | ADORA1 (0.85) | ADORA1ADORA3ADORA2BADORA2A | |
| SCHEMBL5005394 | 0.89 | ADORA1 (0.90) | ADORA1ADORA3ADORA2BADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-03-13 | — | — | US | disclosed |
| US-7265144-B2 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | IAPP, GLP1R, GPR119 | ADORA1 749/4885ADORA3 111/4885ADORA2B 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.